Document 30
CHARMER COMPREHENSIVE GERIATRICIAN-LED MEDICATION REVIEW

COMPREHENSIVE GERIATRICIAN-LEC	MEDICATION REVIEW	NHS Trust Header	•					
Mechanism of Action (MoA) questionnaire								
Participant ID:								
Baseline/Follow-up	(delete as appropria	ite)						
I have the know decision/recom	ledge I need to enak mendations for my p			scribing				
Strongly disagree	Disagree	Neither agree	Agree	Strongly agree				
2. Proactive depre	scribing has more ad	dvantages than disa Neither agree nor disagree	dvantages	Strongly agree				
Strongly disagree	Disagree	Neither agree nor disagree □ □ practice that is acce	Agree	Strongly agree				
Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree				
	I need to enable me pactive deprescribing Disagree			with patients and/or their Strongly agree				
 If I did proactive after. Strongly disagree 	ely deprescribe or re	commend proactive	e deprescrib	ing I would worry about it Strongly agree				
Strongly disagree	_	nor disagree	Agree	Strollgly agree				

 $CHARMER_MOA_Question naire_v1_20220228$

Document 30

CHAR COMPREHENSIVE GERIATRICIAN-LEI	MER D MEDICATION REVIEW	NHS Trust Header				
7. Marking proacti expected of my	•	cisions and/or recom	nmendations is consi	stent with what is		
Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree		
8. I can actively su Strongly disagree	pport deprescribing Disagree	Neither agree	orkload Agree	Strongly agree		
9. My trust has a c	lear policy for depre	Neither agree	Agree	Strongly agree		
10. My department has a clear policy for deprescribing Strongly disagree Disagree Neither agree Agree Strongly agree						
		nor disagree				
11. I feel that depre	escribing efforts in m		<u> </u>	<u> U</u>		
Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree		